172 related articles for article (PubMed ID: 3653718)
1. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment.
Chandler DB; Hida T; Sheta S; Proia AD; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):259-65. PubMed ID: 3653718
[TBL] [Abstract][Full Text] [Related]
2. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.
Chandler DB; Rozakis G; de Juan E; Machemer R
Am J Ophthalmol; 1985 Jun; 99(6):686-90. PubMed ID: 2409802
[TBL] [Abstract][Full Text] [Related]
3. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
Chen EP; Steinhorst UH; Samsa GP; Saloupis PT; Hatchell DL
Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2160-4. PubMed ID: 1607226
[TBL] [Abstract][Full Text] [Related]
4. The lack of an effect of intraocular steroids on irradiated fibroblasts in experimental proliferative vitreoretinopathy.
Chandler DB; Hida T; Rozakis G; Forbes VS; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1992; 230(2):188-91. PubMed ID: 1577303
[TBL] [Abstract][Full Text] [Related]
5. Regular silicone and fluorosilicone oil in the prevention of retinal detachment caused by experimental proliferative vitreoretinopathy.
Alghadyan A; Peyman GA; Fizer C; Tawakol M; Liu KR; Yue B; Peace JH
Int Ophthalmol; 1988 Jan; 11(3):171-4. PubMed ID: 3417389
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.
Khawly JA; Saloupis P; Hatchell DL; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):464-7. PubMed ID: 1937080
[TBL] [Abstract][Full Text] [Related]
7. Taxol treatment of experimental proliferative vitreoretinopathy.
Daniels SA; Coonley KG; Yoshizumi MO
Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):513-6. PubMed ID: 1979953
[TBL] [Abstract][Full Text] [Related]
8. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy.
Ando N; Sen HA; Berkowitz BA; Wilson CA; de Juan E
Arch Ophthalmol; 1994 Jan; 112(1):117-22. PubMed ID: 8285878
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model.
Sunalp M; Wiedemann P; Sorgente N; Ryan SJ
Curr Eye Res; 1984 Apr; 3(4):619-23. PubMed ID: 6425019
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological therapy for proliferative vitreoretinopathy.
Radtke ND; Weinsieder AD; Ballou RJ
Graefes Arch Clin Exp Ophthalmol; 1986; 224(3):230-3. PubMed ID: 3710177
[TBL] [Abstract][Full Text] [Related]
11. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.
Tano Y; Chandler D; Machemer R
Am J Ophthalmol; 1980 Dec; 90(6):810-6. PubMed ID: 7446668
[TBL] [Abstract][Full Text] [Related]
12. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
Steinhorst UH; Chen EP; Machemer R; Hatchell DL
Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
[TBL] [Abstract][Full Text] [Related]
13. Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.
Yang CM; Olsen KR; Hernandez E; Cousins SW
Graefes Arch Clin Exp Ophthalmol; 1992; 230(1):66-71. PubMed ID: 1547971
[TBL] [Abstract][Full Text] [Related]
14. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring.
Ward T; Hartzer M; Blumenkranz M; Lin LR
Curr Eye Res; 1993 May; 12(5):397-401. PubMed ID: 8344064
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.
Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y
Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416
[TBL] [Abstract][Full Text] [Related]
16. Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit.
Sunalp MA; Wiedemann P; Sorgente N; Ryan SJ
Exp Eye Res; 1985 Jul; 41(1):105-15. PubMed ID: 4029281
[TBL] [Abstract][Full Text] [Related]
17. Intraocular injection of silicone oil for experimental proliferative vitreoretinopathy.
Fastenberg DM; Diddie KR; Delmage JM; Dorey K
Am J Ophthalmol; 1983 May; 95(5):663-7. PubMed ID: 6846457
[TBL] [Abstract][Full Text] [Related]
18. Experimental model of proliferative vitreoretinopathy (PVR) in the vitrectomised eye: effect of silicone oil.
Lean JS; van der Zee WA; Ryan SJ
Br J Ophthalmol; 1984 May; 68(5):332-5. PubMed ID: 6712912
[TBL] [Abstract][Full Text] [Related]
19. Silicone oil for retinal detachment with advanced proliferative vitreoretinopathy following failed vitrectomy for proliferative diabetic retinopathy.
Rinkoff JS; de Juan E; McCuen BW
Am J Ophthalmol; 1986 Feb; 101(2):181-6. PubMed ID: 3946533
[TBL] [Abstract][Full Text] [Related]
20. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy.
Arroyo MH; Refojo MF; Araiz JJ; Tolentino FI; Cajita VN; Elner VM
Retina; 1993; 13(3):245-50. PubMed ID: 8235109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
